ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

New Drugs Improve Outlook For Bone Marrow Cancer

March 31, 2006

ACS Community Demonstration Projects Complete, Reach Target Populations, Teach Many Lessons

June 25, 1993

FDA Vs. NCI: Nothing Has Changed; Chabner “Frustrated” By Flutamide Delay

October 21, 1988

ACCC Annual Meeting Expands to 4 Days, One On Cancer Control

January 15, 1982

Conversation With The Cancer Letter: Seffrin To Retire After Restructuring ACS

January 24, 2014

September issue of Business & Regulatory Report included (8-page issue).

October 4, 2002